Generics
Endo unveils authorised generic INVANZ in the US
30 July 2018 -

Pharmaceutical company Endo International plc (NASDAQ:ENDP) reported on Friday the start of shipment of the authorised generic version of INVANZ (ertapenem for injection) in the US.

Par Pharmaceutical (Par), the company's operating subsidiary, has begun shipping the authorized generic version of Merck's INVANZ (ertapenem for injection) in the US following an exclusive US supply and distribution agreement with a subsidiary of Merck & Co Inc of Kenilworth, N.J.

For the 12 months ending 31 May 2018, the US sales of INVANZ were approximately USD390m, according to IQVIA data.

INVANZ is reportedly a registered trademark of Merck Sharp & Dohme Corp.

Login
Username:

Password: